Biotech Tricida Hits Ch. 11 In Del. With $350M Debt, Sale Plans
Tricida Inc., a San Francisco-based clinical-stage pharmaceutical company focused on treating chronic kidney disease, filed for bankruptcy in Delaware on Thursday, with roughly $350 million in debt and a restructuring plan...To view the full article, register now.
Already a subscriber? Click here to view full article